Source:http://linkedlifedata.com/resource/pubmed/id/10964988
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2000-10-10
|
pubmed:abstractText |
Diabodies are the recombinant bispecific antibodies (BsAbs), constructed from heterogeneous single-chain antibodies. Usually, diabodies have been prepared from bacterial periplasmic fraction using a co-expression vector (i.e. genes encoding two chains were tandemly located under the same promoter). Some diabodies, however, cannot be expressed as a soluble material owing to inclusion body formation, which limits the utilization of diabodies in various fields. Here we report an improved method for the construction of diabodies using a refolding system. As a model, a bispecific diabody binding to adenocarcinoma-associated antigen MUC1 and to CD3 on T cells was studied. One chain consisted of a VH specific for MUC1 linked to a VL specific for CD3 with a short polypeptide linker (GGGGS). The second was composed of a VL specific for MUC1 linked to a VH specific for CD3. The two hetero scFvs were independently obtained from intracellular insoluble fractions of Escherichia coli, purified, mixed stoichiometrically (at an equivalent molar ratio of 1:1) and refolded. The refolded two hetero scFv has a hetero-dimeric structure, with complete specificity for both target cells [i.e. MUC1 positive cells and CD3 positive lymphokine-activated killer cells with a T cell phenotype (T-LAK)]. Evaluation of the in vitro efficacy of T-LAK with the diabody by growth inhibition assay of cancer cells demonstrated maximum growth inhibition of cancer cells to reach approximately 98% at an effector:target ratio (E:T ratio) of 10, almost identical with that with anti-MUC1xanti-CD3 chemically synthesized BsAbs (c-BsAbs). This is the first report of the construction of a diabody using a refolding system.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0269-2139
|
pubmed:author |
pubmed-author:AsanoRR,
pubmed-author:EbaraSS,
pubmed-author:ImaiKK,
pubmed-author:KatayoseYY,
pubmed-author:KodamaHH,
pubmed-author:KudoTT,
pubmed-author:KumagaiII,
pubmed-author:MatsunoSS,
pubmed-author:SakuraiNN,
pubmed-author:SuzukiMM,
pubmed-author:TakemuraSS,
pubmed-author:TsumotoKK,
pubmed-author:YoshidaHH
|
pubmed:issnType |
Print
|
pubmed:volume |
13
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
583-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10964988-Antibodies, Bispecific,
pubmed-meshheading:10964988-Cell Division,
pubmed-meshheading:10964988-Escherichia coli,
pubmed-meshheading:10964988-Flow Cytometry,
pubmed-meshheading:10964988-Molecular Weight,
pubmed-meshheading:10964988-Protein Folding,
pubmed-meshheading:10964988-Recombinant Proteins
|
pubmed:year |
2000
|
pubmed:articleTitle |
Construction of a diabody (small recombinant bispecific antibody) using a refolding system.
|
pubmed:affiliation |
First Department of Surgery, School of Medicine, Tohoku University, Sendai, Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|